Clover Health (NASDAQ:CLOV) sees a 53% increase in membership, reaching approximately 153,000 members as of January 1, 2026.The company is on track to achieve GAAP profitability by 2026, with strong member retention rates exceeding 95% and improved margins.Despite a 18.3% decline in CLOV shares over the past six months, Clover Health's strategic expansions and technology enhancements signal potential for future growth.Clover Health Investments, listed as NASDAQ:CLOV, is a healthcare technology company focus ...

Core Viewpoint - The supportive regulatory environment in China and its large market size are driving the growth of artificial intelligence in the healthcare sector [1] Company Insights - Yidu Tech's founder and Chairlady Gong Yingying emphasizes the collaboration between AI and doctors to enhance patient healthcare [1]

编辑：罗浩 目前，该产品已进入实际应用阶段，主要面向临床、科研领域的医生群体。阿里健康此前在财报中透 露，其自研医学大模型正在积极探索在严肃医疗领域的应用场景，致力增强模型在临床决策、临床科研 等关键环节的AI循证能力。此次，"氢离子"正是该模型能力的首个产品化体现。 转自：新华财经 据了解，阿里巴巴已通过通义千问、蚂蚁阿福布局C端健康服务。高门槛、高专业性的严肃医疗场景应 用，则交由深耕医疗健康领域十余年的阿里健康承接。至此，阿里在医疗健康领域的AI布局已实 现"C+D"端布局。 新华财经北京1月19日电（记者沈寅飞）记者从阿里健康获悉，近日，阿里健康AI产品"氢离子"已完成 内测并开放下载。 ...

GE HealthCare Technologies Inc. (GEHC) is a Chicago-based global healthcare technology company that designs, manufactures, and markets advanced medical technologies, diagnostic imaging systems, patient care solutions, and pharmaceutical diagnostics used by hospitals and health networks worldwide. Valued at $38.6 billion by market cap, the company operates through key segments including medical imaging, advanced visualization, patient care solutions, and diagnostics, while also delivering digital infrastruc ...

Core Insights - HealthEquity is focused on modernizing its platform to enhance its operational efficiency and engagement with users [2] - The company serves over 17 million consumer-directed benefit accounts and manages over $34 billion in Health Savings Account (HSA) assets, positioning itself as a leader in the U.S. HSA market [3] Company Overview - HealthEquity operates the leading HSA platform in the United States, emphasizing its scale and market presence [3] - The leadership team, including the CEO and founder, is committed to executing a disciplined strategy to strengthen the company's foundation and create a sustainable business model [2] Strategic Focus - The company has implemented a focused playbook aimed at driving engagement and operational discipline, which is crucial for its long-term success [2] - The modernization of the platform is a key initiative to transform HealthEquity into a true platform company, enhancing its service offerings [2]

Semler Scientific shareholders have approved the healthcare technology firm's deal to be acquired by Strive Inc. in an all-stock transaction, which was first announced last September. When the deal is complete, Strive will become the 11th largest publicly traded holder of Bitcoin. But investors don't seem particularly optimistic on the news. Strive shares, which trade on the Nasdaq as ASST, have plunged nearly 13% on the news. The stock recently changed hands for $0.96. Meanwhile, Semler Scientific, whi ...

CANTON, Mass.--(BUSINESS WIRE)--MEDITECH has announced the go-live of the first large-scale wave of its enterprise-wide MEDITECH Expanse EHR implementations at HCA Healthcare, one of the nation's leading providers of healthcare. This milestone brings the innovative, cloud-based system live at 43 hospitals across the HCA Healthcare network, a key step in supporting the goal of delivering care efficiently, consistently, and safely for the patients and communities HCA Healthcare serves. HCA Healthcare, one of ...

BEIJING, China, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pheton Holdings Ltd (the “Company” or “Pheton”), a healthcare solution provider specializing in treatment planning systems for brachytherapy and other related products and services, announced today that it will change its corporate name to iTonic Holdings Ltd, and change its stock ticker symbol to "ITOC" (collectively, the "Corporate Events"). The Company anticipates that the Corporate Events will be effective upon the commencement of trading on the Nasdaq C ...

Core Insights - Aclarion has successfully strengthened its balance sheet and extended its cash runway into 2028 through a $10.4 million financing, enhancing its operational flexibility and supporting its commercialization efforts for Nociscan [2][3][5] Financial Performance - For the three months ended May 31, 2024, Aclarion reported total revenues of $5.031 million, a 40% increase from $3.603 million in the same period of 2023 [1] - The revenue breakdown includes: - Fluxing Systems: $134,000 (2% of total), down 43% from $236,000 (6% of total) - Integrated Coating Systems: $747,000 (15% of total), up 142% from $309,000 (9% of total) - Multi-Axis Coating Systems: $2.664 million (53% of total), up 51% from $1.763 million (49% of total) - OEM Systems: $332,000 (7% of total), up 21% from $274,000 (8% of total) - Spare Parts, Services, and Other: $1.154 million (23% of total), up 13% from $1.021 million (28% of total) [1] Capital Structure - Aclarion's balance sheet is now debt-free with $21.6 million in cash as of January 12, 2026, allowing for a significant extension of its cash runway [6] - The financing has preserved the integrity of the capital structure and supports ongoing commercialization and strategic partnerships [3][4] Strategic Focus - The company aims to enhance the adoption of Nociscan, deepen clinical evidence, and build strategic relationships to drive growth for patients, providers, payers, and shareholders [5] - Upcoming milestones include accelerating enrollment in the CLARITY trial, expanding access to major MRI manufacturers, and collaborating with commercial payers for reimbursement coverage of Nociscan [11]

Debt-Free Balance Sheet With $21.6 Million in CashBROOMFIELD, Colo., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the closing of a $10.4 million common-stock-only financing at $5.18 per share in a clean capital raise structure. The trans ...